Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US9532987B2 · kind B2 · utility
1Cited by
16References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2014 |
| Grant date | Jan 3, 2017 |
| Priority date | — |
| Expiry date | Sep 20, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.